About OA and HTN
Osteoarthritis (OA) is the most common type of arthritis, causing the loss of cartilage, decreased mobility, and significant pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in treating OA pain, however, they have a significant deleterious side effect — elevated blood pressure — which can cause hypertension (HTN). Known as the “silent killer,” HTN increases the risk of heart attack, stroke and death. As such, many sufferers of OA, whose incidence increases with age, do not receive NSAIDs due to the patients’ and their physicians’ fear of elevated blood pressure. Of the 27 million Americans with OA, 50% also suffer from HTN. Yet there is no single medication or combination drug on the market that simultaneously treats both OA and HTN.
About Combination Drugs
Kitov focuses on the development of combination drugs — medications that integrate two effective drugs into one unit. Aiming to improve the medical treatment of patients suffering from two or more diseases, combination drugs typically incur far less development costs than new chemical entities. In addition, combination drugs reduce development risk, since their component drugs already maintain a proven efficacy and safety profile in the market. Recognizing that there is currently no single medication on the market that treats both OA pain and HTN simultaneously, Kitov has focused on the development of combination drugs treating these two conditions at the same time.
Kitov Intellectual Property
We own one issued patent in the U.S., covering KIT-302, and several pending patent applications. The claimed subject matter in the patent applications would include claims to new treatment methods using known compounds and new formulations and dosage types including unique combinations of known compounds.
Kitov Product Pipeline
Kitov is developing KIT-302: a combination of two drug products that treat OA pain and HTN simultaneously.